SOUTH SAN FRANCISCO, Calif.,
Nov. 30, 2016 /PRNewswire/ --
VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage
biopharmaceutical company focused on developing new generation
therapies for depression and other central nervous system
(CNS) disorders, today announced that Shawn Singh, Chief Executive Officer, will
present at the 9th Annual LD Micro Main Event Conference
on Wednesday, December 7, 2016, at
12:30 p.m. PT, at the Luxe Sunset
Boulevard Hotel in Los
Angeles.
During his presentation, Mr. Singh will provide an update on the
Company's corporate progress and anticipated milestones for AV-101,
its new generation, orally available CNS prodrug candidate in Phase
2 development, initially for the adjunctive treatment of major
depressive disorder (MDD) in patients with an inadequate response
to standard FDA-approved antidepressants.
A live webcast of the presentation will be available by
accessing the IR Calendar in the Investors section of VistaGen's
website (www.vistagen.com). A replay of the webcast will be
available for 90 days, starting approximately two hours after the
presentation ends.
About AV-101
AV-101 (4-CI-KYN) is an orally
available CNS prodrug candidate, currently in Phase 2 development,
initially for the adjunctive treatment of MDD in patients with an
inadequate response to standard FDA-approved antidepressants.
AV-101 also has broad potential utility in other CNS disorders,
including chronic neuropathic pain and epilepsy, as well as
neurodegenerative diseases, such as Parkinson's disease and
Huntington's disease.
AV-101's mechanism of action is fundamentally differentiated
from all FDA-approved antidepressants, with potential to drive a
paradigm shift towards a new generation of safer and faster-acting
antidepressants. Unlike standard antidepressants which act on
serotonin and related neurotransmitter pathways in the brain,
AV-101 works through an entirely different mechanism, mobilizing
glutamate pathways to enhance neuronal plasticity and improve the
communication between neuronal cells. Dysfunction in these
activities is increasingly recognized by scientists as an important
contributor to depression and other serious CNS disorders.
AV-101 is currently being evaluated in a Phase 2a monotherapy
study in MDD. This study is being fully funded by the U.S. National
Institute of Mental Health (NIMH), part of the U.S. National
Institutes of Health (NIH). The Principal Investigator of
the study is Dr. Carlos Zarate Jr.,
Chief, Section on the Neurobiology and Treatment of Mood Disorders
and Chief of Experimental Therapeutics and Pathophysiology Branch
at the NIMH.
VistaGen is preparing to advance AV-101 into a 280-patient, U.S.
multi-center, Phase 2b adjunctive treatment study in MDD in the
first half of 2017, prior to the completion of the NIMH-sponsored
AV-101 Phase 2a monotherapy study. The Principal Investigator of
the Phase 2b adjunctive treatment study will be Dr. Maurizio Fava of Harvard
University.
About VistaGen
VistaGen Therapeutics, Inc. (NASDAQ:
VTGN), is a clinical-stage biopharmaceutical company focused on
developing new generation therapies for depression and other CNS
disorders. VistaGen's lead CNS product candidate, AV-101, is a new
generation, orally available prodrug in Phase 2 development,
initially for the adjunctive treatment of MDD in patients with
inadequate response to standard FDA-approved antidepressants.
AV-101 is currently being evaluated in an NIMH-sponsored Phase 2a
monotherapy study in MDD being conducted by Principal Investigator,
Dr. Carlos Zarate Jr., of the NIMH.
VistaGen is preparing to initiate an AV-101 Phase 2b adjunctive
treatment study, in MDD patients with an inadequate response to
standard FDA-approved antidepressants, in the first half of
2017.
For more information, please visit www.vistagen.com and connect
with VistaGen on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
The statements in this
press release that are not historical facts may constitute
forward-looking statements that are based on current expectations
and are subject to risks and uncertainties that could cause actual
future results to differ materially from those expressed or implied
by such statements. Those risks and uncertainties include, but are
not limited to, risks related to the results of Phase 2a and Phase
2b clinical studies of AV-101 for treatment of MDD and other CNS
diseases and disorders, protection of its intellectual property,
and availability of substantial additional capital to support its
operations, including the clinical development activities described
above. These and other risks and uncertainties are identified and
described in more detail in VistaGen's filings with the Securities
and Exchange Commission (SEC). These filings are available
on the SEC's website at www.sec.gov. VistaGen undertakes no
obligation to publicly update or revise any forward-looking
statements.
Logo - http://photos.prnewswire.com/prnh/20160321/346644LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/vistagen-therapeutics-to-present-at-9th-annual-ld-micro-main-event-300370213.html
SOURCE VistaGen Therapeutics, Inc.